| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.0096 | 0.9 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | Roscovitine | FIMM | pan-cancer | AAC | -0.032 | 0.9 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | vorapaxar | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |